Measles Vaccine Is Gain-of-Function Product, Even On Mainstream Disease Model: CD150/CD46 Tropism

No studies confirm the measles vaccine virus is less infectious or replicates less in humans than the wild-type measles virus.
Jon Fleetwood

Sources: The Journal of Infectious Diseases (2015) and Congressional Research Service (CRS). The peer-reviewed journal identifies the development of the live-attenuated measles vaccine through repeated passage and altered viral tropism as potentially qualifying as gain-of-function research, while Congress’s research service defines GOF as genetic mutations that confer “a new or enhanced ability.”

On the mainstream virological model, a May 2016 publication in The Journal of Infectious Diseases by U.S. military biodefense experts states that the live-attenuated measles vaccine was created by a process that “could be considered, by current definitions, GOF research.”

The paper states: “The live-attenuated measles vaccine was created by passaging the virus until mutations arose that altered virus tropism—a technique that could be considered, by current definitions, GOF research.”

Keep reading: https://jonfleetwood.substack.com/p/measles-vaccine-is-gain-of-function